Skip to main content
. 2018 Jan 11;4:JGO.17.00077. doi: 10.1200/JGO.17.00077

Fig 2.

Fig 2

Trajectories of health-related quality-of-life scores using the Functional Assessment Cancer Therapy-Kaposi Sarcoma score with the corresponding 95% CIs over follow-up. Participants in the bleomycin plus vincristine (BV) and gemcitabine arms improved in function, but neither arm was statistically improved compared with the other, because the CIs overlap. Thin black lines represent BV CIs; dashed red lines represent gemcitabine CIs.